Mark Underwood

5.0k citations
55 papers · 2.8k · 1 hit paper · h-index 25

Impact in

  • Virology top 0.5%
    • HIV Research and Treatment
  • Infectious Diseases top 0.5%
    • HIV/AIDS drug development and treatment
    • HIV/AIDS Research and Interventions

Papers in

  • Infectious Diseases 35
    • HIV/AIDS drug development and treatment 35
    • HIV/AIDS Research and Interventions 7
  • Virology 22
    • HIV Research and Treatment 22
Co-authors
Tamio Fujiwara (10 shared papers)Karen K. Biron (9 shared papers)John C. Drach (7 shared papers)Leroy B. Townsend (6 shared papers)Brian A. Johns (6 shared papers)Takahiro Seki (7 shared papers)Akihiko Sato (8 shared papers)Howard M. Fried (1 shared paper)
Journals
Antimicrobial Agents and Chemotherapy (8 papers)Antiviral Research (4 papers)Journal of Virology (4 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (4 papers)Open Forum Infectious Diseases (4 papers)
Partner nations
United StatesUnited KingdomJapan

In The Last Decade

Mark Underwood

53 papers receiving 2.7k citations

Mark Underwood's Hit Papers

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies 2018 · 246 citations
2460+2+5Years since publication50100150200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2018 The Lancet

Peers

Mark Underwood
Comparison fields: 5 of 104
  • Virology 1.0k
  • Infectious Diseases 1.8k
  • Epidemiology 722
  • Emergency Medicine 164
  • Parasitology 101
Replace Marty St. Clair with:
Marty St. Clair United States
David Marchant Canada
Andrea Costantini Italy
Ryuji Kawaguchi Japan
William J. Cronin United States
Feili Wei China
José Azócar United States
Daniel S Berger United States
Pierrick Uzureau Belgium
Reinhard Kirsch Germany
Mark Underwood relative to Marty St. Clair United States Marty St. Clair's profile →
Citations per field
00.5×10×20×25.3×
Marty St. Clair · 1×
Citations per year

Countries citing papers authored by Mark Underwood

Since Specialization
Citations

This map shows the geographic impact of Mark Underwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Underwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Underwood more than expected).

Fields of papers citing papers by Mark Underwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Underwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Underwood. The network helps show where Mark Underwood may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Underwood, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Underwood Line = papers co-authored together Mark Underwood links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#Work
1
In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Antimicrobial Agents and Chemotherapy ·Masanori Kobayashi, Tomokazu Yoshinaga, Takahiro Seki, Chiaki Wakasa-Morimoto, Kevin Brown, Robert G. Ferris, Scott A. Foster, Richard Hazen, Shigeru Miki, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A. Johns, Mark Underwood, Edward P. Garvey, Akihiko Sato, Tamio Fujiwara
2010319
2
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
The Lancet ·Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre‐Marie Girard, Lesley Kahl, Elizabeth A. Blair, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Mark Underwood, K. Smith, Martin Gartland, Michael Aboud
Hit paper breakdown →		2018246
3
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
Journal of Virology ·Peter K. Quashie, Thibault Mésplède, Ying-Shan Han, Maureen Oliveira, Diane N. Singhroy, Tamio Fujiwara, Mark Underwood, Mark A. Wainberg
2011198
4
Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
Antimicrobial Agents and Chemotherapy ·Kendra E. Hightower, Ruolan Wang, Felix Deanda, Brian A. Johns, Kurt Weaver, Yingnian Shen, Ginger H. Tomberlin, H. Luke Carter, Timothy M Broderick, Sigethy Scott, Takahiro Seki, Masanori Kobayashi, Mark Underwood
2011182
5
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
AIDS ·Sherene Min, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy, Ivy Song, Richard Stroder, Shuguang Chen, Mark Underwood, Tamio Fujiwara, Stephen C. Piscitelli, Jay Lalezari
2011173
6
Inhibition of Human Cytomegalovirus DNA Maturation by a Benzimidazole Ribonucleoside Is Mediated through the UL89 Gene Product
Journal of Virology ·Mark Underwood, (unknown), Sylvia C. Stanat, Mary Lou Hemphill, Teresa Miller, John C. Drach, Leroy B. Townsend, Karen K. Biron
1998169
7
Resistance of Human Cytomegalovirus to Benzimidazole Ribonucleosides Maps to Two Open Reading Frames: UL89 and UL56
Journal of Virology ·Paula M. Krosky, Mark Underwood, Steven R. Turk, Kathryne W.-H. Feng, Rajeev Jain, Roger G. Ptak, A. C. WESTERMAN, Karen K. Biron, Leroy B. Townsend, John C. Drach
1998148
8
In Vitro Activities of Benzimidazole d - and l -Ribonucleosides against Herpesviruses
Antimicrobial Agents and Chemotherapy ·Stephanie L. Williams, Caroll B. Hartline, Nicole L. Kushner, Emma A. Harden, Deborah J. Bidanset, John C. Drach, Leroy B. Townsend, Mark Underwood, Karen K. Biron, Earl R. Kern
2003125
9
Groundwater lens dynamics of Atoll Islands
Water Resources Research ·Mark Underwood, Frank L. Peterson, Clifford I. Voss
1992115
10
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
The Lancet Infectious Diseases ·Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Judy Hopking, Mark Underwood, Maria Cláudia Nascimento, Yogesh Punekar, Martin Gartland, Kimberly Y. Smith
2019106
11
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Clinical Infectious Diseases ·Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Stephen Taylor, Elizabeth A. Blair, Choy Man, Brian Wynne, J Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk
202290
12
Characterization of nuclear localizing sequences derived from yeast ribosomal protein L29.
The EMBO Journal ·Mark Underwood, Howard M. Fried
199085
13
Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
Antimicrobial Agents and Chemotherapy ·Tomokazu Yoshinaga, Masanori Kobayashi, Takahiro Seki, Shigeru Miki, Chiaki Wakasa-Morimoto, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A. Johns, Mark Underwood, Edward P. Garvey, Akihiko Sato, Tamio Fujiwara
201483
14
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
The Lancet HIV ·Michael Aboud, Chloe Orkin, Daniel Podzamczer, Johannes R. Bogner, David Baker, Marie-Aude Khuong-Josses, David Parks, Konstantinos Angelis, Lesley Kahl, Elizabeth A. Blair, Kimberly K. Adkison, Mark Underwood, Jessica Matthews, Brian Wynne, Kati Vandermeulen, Martin Gartland, Kimberly Y. Smith
201978
15
The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mark Underwood, Brian A. Johns, Akihiko Sato, Jeffrey N. Martin, Steven G. Deeks, Tamio Fujiwara
201273
16
The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients
Antimicrobial Agents and Chemotherapy ·Fausto Baldanti, Mark Underwood, Christine L. Talarico, L. Simoncini, Antonella Sarasini, Karen K. Biron, Giuseppe Gerna
199859
17
Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics
Antiviral Research ·Koichiro Nakahara, Chiaki Wakasa-Morimoto, Masanori Kobayashi, Shigeru Miki, Takeshi Noshi, Takahiro Seki, Mikiko Kanamori-Koyama, Shinobu Kawauchi, Akemi Suyama, Toshio Fujishita, Tomokazu Yoshinaga, Edward P. Garvey, Brian A. Johns, Scott A. Foster, Mark Underwood, Akihiko Sato, Tamio Fujiwara
200846
18
Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
PLoS ONE ·Felix Deanda, Kendra E. Hightower, Robert T. Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark Underwood
201344
19
Mechanism of Action of the Ribopyranoside Benzimidazole GW275175X against Human Cytomegalovirus
Antimicrobial Agents and Chemotherapy ·Mark Underwood, Robert G. Ferris, Dean W. Selleseth, Michelle G. Davis, John C. Drach, Leroy B. Townsend, Karen K. Biron, F. Leslie Boyd
200441
20
Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease
Advances in experimental medicine and biology ·Jeffrey D. Chulay, Karen K. Biron, Laurene Wang, Mark Underwood, Stanley D. Chamberlain, Lloyd Frick, Steven S. Good, M G Davis, (unknown), Leroy B. Townsend, John C. Drach, George W. Koszalka
199939

About Mark Underwood

Mark Underwood is a scholar working on Infectious Diseases, Virology, Molecular Biology, Epidemiology and Genetics, having authored 55 papers that have together received 2.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (22 papers), Biochemical and Molecular Research (10 papers), Cytomegalovirus and herpesvirus research (9 papers), HIV/AIDS Research and Interventions (7 papers), Herpesvirus Infections and Treatments (6 papers), Hepatitis B Virus Studies (4 papers) and Hepatitis C virus research (3 papers). The work is most often cited by research in Virology (1.0k citations), Infectious Diseases (1.8k citations), Epidemiology (722 citations), Emergency Medicine (164 citations) and Parasitology (101 citations). Mark Underwood has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Tamio Fujiwara, Karen K. Biron, John C. Drach, Leroy B. Townsend, Brian A. Johns, Takahiro Seki, Akihiko Sato, Howard M. Fried, Frank L. Peterson and Tomokazu Yoshinaga. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Antiviral Research, Journal of Virology, JAIDS Journal of Acquired Immune Deficiency Syndromes and Open Forum Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marty St. ClairBreakdown of academic impact, for papers by David MarchantBreakdown of academic impact, for papers by Andrea CostantiniBreakdown of academic impact, for papers by Ryuji KawaguchiBreakdown of academic impact, for papers by William J. CroninBreakdown of academic impact, for papers by Feili WeiBreakdown of academic impact, for papers by José AzócarBreakdown of academic impact, for papers by Daniel S BergerBreakdown of academic impact, for papers by Pierrick UzureauBreakdown of academic impact, for papers by Reinhard Kirsch